VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Thursday morning. The firm issued a sell rating on the stock.

Several other research firms have also recently weighed in on VNRX. D. Boral Capital reissued a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a report on Wednesday, March 12th. Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.54 on Thursday. The firm’s 50 day moving average price is $0.60 and its 200-day moving average price is $0.64. The company has a market cap of $50.44 million, a PE ratio of -1.51 and a beta of 1.09. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.02.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Northern Trust Corp increased its holdings in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in VolitionRx during the fourth quarter valued at approximately $29,000. Millennium Management LLC purchased a new stake in VolitionRx during the fourth quarter valued at approximately $36,000. Geode Capital Management LLC increased its holdings in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. increased its holdings in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares during the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.